Needham Maintains Buy on NeoGenomics, Raises Price Target to $22

Needham analyst Mike Matson has maintained a 'Buy' rating on NeoGenomics (NASDAQ: NEO) and raised the price target from $19 to $22. This adjustment reflects a positive outlook for the company's performance in the market.